REG - GSK PLC - Director/PDMR Shareholding

GSKAnnouncement

19/02/2024 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240219:nRSS6609Da&default-theme=true

RNS Number : 6609D  GSK PLC  19 February 2024

GSK plc (the 'Company')

Transaction notification

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Emma Walmsley
 b)  Position/status                          Chief Executive Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                The vesting of Ordinary Shares awarded in 2019 under the Company's 2017

                                        Performance Share Plan and subject to an additional vesting period of two
                                              years from the normal vesting date

 c)  Price(s) and volume(s)                                        Price(s)             Volume(s)
                                                                   £0.00                297,428.535

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2024-02-16
 f)  Place of the transaction                 N/A

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Emma Walmsley
 b)  Position/status                          Chief Executive Officer
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63
 b)  Nature of the transaction                The sale of Ordinary Shares to meet tax liabilities on the vesting of awards
                                              granted in 2019 under the Company's 2017 Performance Share Plan and subject to
                                              an additional vesting period of two years from the normal vesting date
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £16.5797              139,792

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2024-02-16
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSFAFIUELSEFE